Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121434569
rs121434569
0.040 GeneticVariation BEFREE The EGFR resistance mutation T790M should be monitored at cancer progression. 31445213

2019

dbSNP: rs121434569
rs121434569
0.040 GeneticVariation BEFREE Liquid biopsies (LB) are used routinely in clinical practice in two situations for late stage non-small-cell lung cancer (NSCLC) patients, (i) at the initial diagnosis when looking for activating mutations in EGFR in the absence of analyzable tissue DNA and, (ii) during tumor progression on a tyrosine kinase inhibitor treatment to look for the resistance mutation T790M in EGFR. 29069959

2017

dbSNP: rs121434569
rs121434569
0.040 GeneticVariation BEFREE Finally, in the prospective series, SiRe detected 8.7% (4/46) of EGFR mutations at baseline and 42.9% (9/21) of EGFR p.T790M in patients at tumour progression. 28170370

2017

dbSNP: rs121434569
rs121434569
0.040 GeneticVariation BEFREE Detection of T790M with plasma DNA was correlated with EGFR mutation type, exon 19 deletions and tumor progression. 26577492

2016

dbSNP: rs961150162
rs961150162
0.010 GeneticVariation BEFREE The DDR2 E655K mutation can play a role in cancer progression by reducing the growth-inhibitory effect of collagen. 26826182

2016

dbSNP: rs1057519847
rs1057519847
0.010 GeneticVariation BEFREE Haploinsufficiency of Nkx2-1 enhanced Kras(G12D)-mediated tumor progression, but reduced EGFR(L858R)-mediated progression. 23143308

2012

dbSNP: rs1057519848
rs1057519848
0.010 GeneticVariation BEFREE Haploinsufficiency of Nkx2-1 enhanced Kras(G12D)-mediated tumor progression, but reduced EGFR(L858R)-mediated progression. 23143308

2012

dbSNP: rs121434568
rs121434568
0.010 GeneticVariation BEFREE Haploinsufficiency of Nkx2-1 enhanced Kras(G12D)-mediated tumor progression, but reduced EGFR(L858R)-mediated progression. 23143308

2012

dbSNP: rs2227983
rs2227983
0.010 GeneticVariation BEFREE The common EGFR-R521K genotype (G/G) was significantly associated with increased skin toxicity (P = 0.024) and showed a trend toward reduced risk of tumor progression (hazard ratio, 0.55; 95% confidence interval, 0.27-1.08; P = 0.08), whereas no correlation of the EGFR-R521K genotype with OS could be observed (P = 0.20). 20028750

2010